(Q36854826)

English

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

scientific article published on June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

abiraterone acetate

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Mary-Ellen Taplin

5

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

12

object named as

Eric J Small

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Charles J Ryan

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Shreya Shah

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Eleni Efstathiou

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Matthew R Smith

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Glenn J Bubley

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Christopher J Logothetis

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Thian Kheoh

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Christine Kilian

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Christopher M Haqq

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Arturo Molina

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

1 June 2011

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

17

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

14

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4854-4861

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Osteoblastic response to successful treatment of metastatic cancer of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

29 September 2017

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

4 September 2018

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

4 September 2018

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3657705

4 September 2018

Osteocalcin: a potential marker of metastatic bone disease and response to treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21632851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan

1 reference

https://pubmed.ncbi.nlm.nih.gov/21632851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21632851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative bone scintigraphy in prostatic carcinoma--long-term response to treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/21632851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Healing flare in skeletal metastases from breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21632851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21632851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-11-0815

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36854826&oldid=2186406365"